|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM159 |
Gene summary for TMEM159 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM159 | Gene ID | 57146 |
| Gene name | lipid droplet assembly factor 1 | |
| Gene Alias | TMEM159 | |
| Cytomap | 16p12.3 | |
| Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | Q96B96 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57146 | TMEM159 | LZE2T | Human | Esophagus | ESCC | 4.83e-04 | 2.04e-01 | 0.082 |
| 57146 | TMEM159 | LZE3D | Human | Esophagus | HGIN | 2.55e-04 | 7.15e-01 | 0.0668 |
| 57146 | TMEM159 | LZE4T | Human | Esophagus | ESCC | 1.38e-14 | 5.40e-01 | 0.0811 |
| 57146 | TMEM159 | LZE5T | Human | Esophagus | ESCC | 1.46e-04 | 2.30e-01 | 0.0514 |
| 57146 | TMEM159 | LZE7T | Human | Esophagus | ESCC | 6.30e-06 | 2.66e-01 | 0.0667 |
| 57146 | TMEM159 | LZE8T | Human | Esophagus | ESCC | 8.92e-05 | 2.60e-01 | 0.067 |
| 57146 | TMEM159 | LZE20T | Human | Esophagus | ESCC | 4.26e-07 | 1.31e-01 | 0.0662 |
| 57146 | TMEM159 | LZE22T | Human | Esophagus | ESCC | 1.72e-03 | 3.04e-01 | 0.068 |
| 57146 | TMEM159 | LZE24T | Human | Esophagus | ESCC | 8.20e-14 | 3.72e-01 | 0.0596 |
| 57146 | TMEM159 | LZE21T | Human | Esophagus | ESCC | 1.47e-03 | 4.46e-01 | 0.0655 |
| 57146 | TMEM159 | P1T-E | Human | Esophagus | ESCC | 1.66e-10 | 1.03e+00 | 0.0875 |
| 57146 | TMEM159 | P2T-E | Human | Esophagus | ESCC | 3.06e-74 | 1.27e+00 | 0.1177 |
| 57146 | TMEM159 | P4T-E | Human | Esophagus | ESCC | 3.70e-28 | 8.34e-01 | 0.1323 |
| 57146 | TMEM159 | P5T-E | Human | Esophagus | ESCC | 1.04e-26 | 5.35e-01 | 0.1327 |
| 57146 | TMEM159 | P8T-E | Human | Esophagus | ESCC | 2.16e-35 | 6.13e-01 | 0.0889 |
| 57146 | TMEM159 | P9T-E | Human | Esophagus | ESCC | 2.99e-10 | 2.19e-01 | 0.1131 |
| 57146 | TMEM159 | P10T-E | Human | Esophagus | ESCC | 2.48e-03 | -1.68e-02 | 0.116 |
| 57146 | TMEM159 | P11T-E | Human | Esophagus | ESCC | 7.09e-17 | 9.28e-01 | 0.1426 |
| 57146 | TMEM159 | P12T-E | Human | Esophagus | ESCC | 1.81e-37 | 6.92e-01 | 0.1122 |
| 57146 | TMEM159 | P15T-E | Human | Esophagus | ESCC | 5.87e-28 | 6.55e-01 | 0.1149 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM159 | SNV | Missense_Mutation | rs780090255 | c.169N>A | p.Val57Met | p.V57M | Q96B96 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-AN-A0FZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TMEM159 | insertion | Nonsense_Mutation | novel | c.357_358insACCTTGGGAGGCCAAGGCAGGTGGATCACTTGA | p.Gly119_Gly120insThrLeuGlyGlyGlnGlyArgTrpIleThrTer | p.G119_G120insTLGGQGRWIT* | Q96B96 | protein_coding | TCGA-A8-A09T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | ||
| TMEM159 | insertion | Frame_Shift_Ins | novel | c.47_48insC | p.Gln17AlafsTer14 | p.Q17Afs*14 | Q96B96 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
| TMEM159 | insertion | Nonsense_Mutation | novel | c.48_49insACTCCCCTCTGAGTTCCCATTATT | p.Leu16_Gln17insThrProLeuTerValProIleIle | p.L16_Q17insTPL*VPII | Q96B96 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
| TMEM159 | insertion | Frame_Shift_Ins | novel | c.474_475insTGGGAATTGGGGGGACTGG | p.Arg159TrpfsTer17 | p.R159Wfs*17 | Q96B96 | protein_coding | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD | ||
| TMEM159 | SNV | Missense_Mutation | novel | c.76T>A | p.Ser26Thr | p.S26T | Q96B96 | protein_coding | tolerated(0.25) | possibly_damaging(0.689) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| TMEM159 | SNV | Missense_Mutation | c.283C>T | p.Leu95Phe | p.L95F | Q96B96 | protein_coding | tolerated(0.15) | benign(0.09) | TCGA-NH-A6GB-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| TMEM159 | SNV | Missense_Mutation | rs372605849 | c.413N>T | p.Ser138Leu | p.S138L | Q96B96 | protein_coding | deleterious(0.03) | benign(0.044) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TMEM159 | SNV | Missense_Mutation | c.370N>A | p.Leu124Ile | p.L124I | Q96B96 | protein_coding | deleterious(0.01) | possibly_damaging(0.861) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM159 | SNV | Missense_Mutation | novel | c.311C>T | p.Ala104Val | p.A104V | Q96B96 | protein_coding | deleterious(0.04) | probably_damaging(0.997) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |